- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00490646
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
Randomized Phase II Study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects With Her2+ Locally Advanced and/or Metastatic Breast Cancer
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Madrid, Espanja, 28034
- Local Institution
-
Madrid, Espanja, 28007
- Local Institution
-
-
-
-
-
Bologna, Italia, 40138
- Local Institution
-
Brescia, Italia, 25123
- Local Institution
-
Modena, Italia, 41100
- Local Institution
-
Napoli, Italia, 80131
- Local Institution
-
Roma, Italia, 00144
- Local Institution
-
Sora, Italia, 03039
- Local Institution
-
-
-
-
-
Athens, Kreikka, 11522
- Local Institution
-
Athens, Kreikka, 12462
- Local Institution
-
Pireaus, Kreikka, 18537
- Local Institution
-
-
-
-
-
Caen, Ranska, F-14076
- Local Institution
-
Grenoble, Ranska, 38028
- Local Institution
-
St Priest En Jarez, Ranska, 42271
- Local Institution
-
Toulouse, Ranska, 31300
- Local Institution
-
-
-
-
-
Ankara, Turkki, 06100
- Local Institution
-
Ankara, Turkki, 06500
- Local Institution
-
Izmir, Turkki, 35100
- Local Institution
-
Izmir, Turkki, 35340
- Local Institution
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Locally advanced or metastatic HER2+ breast cancer not previously treated with chemotherapy or trastuzumab.
- Subjects who had received prior (neo)adjuvant chemotherapy or trastuzumab were eligible except if they relapsed within 12 months after the last dose of a taxane or trastuzumab given as (neo)adjuvant therapy.
- Measurable disease
- Left Ventricular Ejection Fraction (LVEF) ≥50%
Exclusion Criteria:
- Prior chemotherapy or trastuzumab for metastatic breast cancer (MBC)
- Relapse within 1 year after (neo)adjuvant taxane or trastuzumab
- Neuropathy > Grade 1
- Significant cardiovascular disease
- Any brain metastases
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Arm A
trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
|
Ixabepilone 40 mg/m^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated.
Muut nimet:
Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity.
In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0).
Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
|
Active Comparator: Arm B
trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
|
Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity.
In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0).
Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
Docetaxel 100 mg/m^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.
For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Percentage of Participants With Objective Response (OR; Assessed by Response Evaluation Criteria in Solid Tumors [RECIST] Version 1.1)
Aikaikkuna: Assessed every 6 weeks from initiation of study therapy up to 12 months; then every 3 months until disease progression (maximum time that any participant was on therapy was 108 weeks)
|
Percentage of participants with best overall response (BOR) of either complete response (CR) or partial response (PR) according to RECIST version 1.1 as determined by the investigator.
CR: Disappearance of all evidence of target and non-target lesions.
PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all lesions.
CR and PR criteria should be met again after 4 weeks and before 6 weeks after initial assessment.
A two-sided confidence interval (CI) was computed using the Clopper-Pearson method.
|
Assessed every 6 weeks from initiation of study therapy up to 12 months; then every 3 months until disease progression (maximum time that any participant was on therapy was 108 weeks)
|
Number of Participants With Best Overall Response (BOR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Aikaikkuna: Assessed every 6 weeks from initiation of study therapy up to 12 months; then every 3 months until disease progression (maximum time that any participant was on therapy was 108 weeks).
|
BOR was the best response recorded from the start of treatment until disease progression or recurrence (taking the smallest measurement recorded since the start of treatment as reference).
CR: Disappearance of all evidence of target and non-target lesions.
PR: At least 30% reduction from baseline in the sum of the LD of all lesions.
CR and PR criteria should be met again after 4 weeks and before 6 weeks after initial assessment.
Stable disease (SD)=Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR.
Refer to Outcome Measure 3 for definition of PD.
|
Assessed every 6 weeks from initiation of study therapy up to 12 months; then every 3 months until disease progression (maximum time that any participant was on therapy was 108 weeks).
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Progression Free Survival (PFS)
Aikaikkuna: From randomization until the first date of documented progressive disease (PD) or death from any cause without prior documentation of progression (maximum participant PFS of 39.7 months).
|
Time in months from randomization until first date of documented progressive disease (PD) or death from any cause without prior documentation of progression. PD=≥20% increase in sum of LD of target lesions in reference to smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall. Estimated by the Kaplan-Meier product limit method. A two-sided 95% CI for median duration was computed by the Brookmeyer and Crowley method. |
From randomization until the first date of documented progressive disease (PD) or death from any cause without prior documentation of progression (maximum participant PFS of 39.7 months).
|
Time to Response
Aikaikkuna: From randomization every 6 weeks for first 12 months and thereafter every 3 months until CR or PR whichever was recorded first (maximum participant time to response of 18.4 weeks.)
|
Time to response was defined as the time in weeks from randomization until the measurement criteria are first met for a CR or PR, whichever is recorded first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the LD of all lesions. CR and PR criteria should be met again after 4 weeks and before 6 weeks after initial assessment. Estimated by the Kaplan-Meier product limit method. A two-sided 95% CI for median duration was computed by the Brookmeyer and Crowley method. |
From randomization every 6 weeks for first 12 months and thereafter every 3 months until CR or PR whichever was recorded first (maximum participant time to response of 18.4 weeks.)
|
Duration of Response
Aikaikkuna: From the date of first PR or CR assessment to the date of documented progressive disease or death without prior documentation of progression (maximum participant duration of response of 38 months.)
|
Period measured in months from time that measurement criteria were first met for CR or PR until first date of documented PD or death from any cause without prior documentation of progression. PD=≥20% increase in sum of LD of target lesions in reference to smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall. Refer to Outcome Measure 1 for definitions of CR and PR. Estimated by the Kaplan-Meier product limit method. A two-sided 95% CI for median duration was computed by Brookmeyer and Crowley method. |
From the date of first PR or CR assessment to the date of documented progressive disease or death without prior documentation of progression (maximum participant duration of response of 38 months.)
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs), and AEs Leading to Discontinuation of Study Therapy Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0
Aikaikkuna: Assessed from the date of first dose until at least 30 days after the last dose of study drug (maximum time that any participant was on therapy was 108 weeks.)
|
AE: New untoward medical occurrence or worsening of a preexisting medical condition that does not have causal relationship with this treatment.
SAE: Untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, drug dependency/abuse; life-threatening, an important medical event, a congenital anomaly/birth defect; requires inpatient hospitalization/prolongs existing hospitalization.
Grade 3=Severe; and Grade 4=Life-threatening or disabling.
GR=Grade.
|
Assessed from the date of first dose until at least 30 days after the last dose of study drug (maximum time that any participant was on therapy was 108 weeks.)
|
Number of Participants With Hematology Abnormalities by Worst Grade Per National Cancer Institute Common Terminology Criteria Adverse Events (NCI CTCAE), Version 3.0
Aikaikkuna: Prior to every cycle of therapy (i.e. before starting of every 21 day or 3 week cycle; maximum time that any participant was on therapy was 108 weeks.)
|
Grade (GR)1=mild, GR2=moderate, GR3=severe, GR4=life threatening or disabling.
Normal ranges provided by local laboratory and may also vary by age and sex.
White blood cell (WBC):GR1=<LLN-3.0*10^9/L;
GR2=<3.0-2.0*10^9/L;
GR3=<2.0-1.0*10^9/L;
GR4=<1.0*10^9/L.
Absolute Neutrophil Count (ANC):GR1=<LLN-1.5*10^9
/L; GR2=<1.5-1.0*10^9/L;
GR3=<1.0-0.5*10^9/L;
GR4=<0.5*10^9/L.
Platelets:GR1=<LLN-75.0*10^9/L;
GR2=<75.0-50.0*10^9/L;
GR3=<50.0-25.0*10^9/L,
GR4=<25.0*10^9/L.
Hemoglobin:GR1=<LLN-10.0g/dL; GR2=<10.0-8.0g/dL;
GR3=<8.0-6.5g/dL,
GR4=<6.5g/dL.
LLN=lower limit of normal.
|
Prior to every cycle of therapy (i.e. before starting of every 21 day or 3 week cycle; maximum time that any participant was on therapy was 108 weeks.)
|
Number of Participants With Serum Chemistry Abnormalities by Worst Grade Per National Cancer Institure Common Terminology Criteria Adverse Events (NCI CTCAE), Version 3.0
Aikaikkuna: Prior to every cycle of therapy (i.e. before starting of every 21 day or 3 week cycle; maximum time that any participant was on therapy was 108 weeks.)
|
Grading: NCI CTCAE, Version 3.0.
GR1=mild, GR2=moderate, GR3=severe, GR4=life threatening or disabling.
Normal ranges provided by local laboratory and may also vary by age and sex.
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST): GR1=>ULN-2.5*ULN;
GR2=>2.5-5.0*ULN;
GR3=>5.0-20.0*ULN;
GR4=>20.0*ULN.
Total bilirubin: GR1=>ULN-1.5*ULN,
GR2=>1.5-3.0*ULN,
GR3=>3-10*ULN, GR4=>10*ULN.
Creatinine: GR1=>ULN-1.5*ULN,
GR2=>1.5-3.0*ULN,
GR3=>3.0-6.0*ULN,
GR4=>6.0*ULN.
ULN=upper limit of normal.
|
Prior to every cycle of therapy (i.e. before starting of every 21 day or 3 week cycle; maximum time that any participant was on therapy was 108 weeks.)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Ihosairaudet
- Neoplasmat
- Neoplasmat sivustoittain
- Rintojen sairaudet
- Rintojen kasvaimet
- Farmakologisen vaikutuksen molekyylimekanismit
- Antineoplastiset aineet
- Tubuliinimodulaattorit
- Antimitoottiset aineet
- Mitoosin modulaattorit
- Antineoplastiset aineet, immunologiset
- Doketakseli
- Trastutsumabi
- Epotiloneja
Muut tutkimustunnusnumerot
- CA163-140
- Eudract No: 2007-000721-21
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Metastaattinen rintasyöpä
-
Gangnam Severance HospitalRekrytointiHER2 Rikastettu alatyyppi Breast Cancer, Herzuma, PAM50 -tutkimusKorean tasavalta
-
Novartis PharmaceuticalsValmisMetastaattinen rintasyöpä (MBC) | Locally Advance Breast Cancer (LABC)Yhdistynyt kuningaskunta, Espanja
-
BioNTech SESeventh Framework ProgrammeValmisRintasyöpä (TNBC (Triple Negative Breast Cancer))Ruotsi, Saksa
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Ei vielä rekrytointiaAnatomisen vaiheen II rintasyöpä AJCC v8 | Anatomisen vaiheen III rintasyöpä AJCC v8 | Varhaisen vaiheen rintasyöpä | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Yhdysvallat
-
Emory UniversityNational Cancer Institute (NCI)PeruutettuPrognostisen vaiheen IV rintasyöpä AJCC v8 | Metastaattinen pahanlaatuinen kasvain aivoissa | Metastaattinen rintasyöpä | Anatominen vaihe IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
Fudan UniversityRekrytointiRintasyöpä | Rintojen kasvain | Rintojen kasvaimet | HER2-positiivinen rintasyöpä | Paikallisesti edennyt rintasyöpä | HER2-negatiivinen rintasyöpä | Hormonireseptoripositiivinen kasvain | Hormonireseptorinegatiivinen kasvain | Varhaisvaiheen rintasyöpä | Triple-negative Breast Cancer (TNBC)Kiina
-
NRG OncologyNational Cancer Institute (NCI)Aktiivinen, ei rekrytointiAnatomisen vaiheen IV rintasyöpä AJCC v8 | Prognostisen vaiheen IV rintasyöpä AJCC v8 | Metastaattinen pahanlaatuinen kasvain luussa | Metastaattinen pahanlaatuinen kasvain imusolmukkeissa | Metastaattinen pahanlaatuinen kasvain maksassa | Metastaattinen rintasyöpä | Metastaattinen pahanlaatuinen kasvain... ja muut ehdotYhdysvallat, Kanada, Saudi-Arabia, Korean tasavalta
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)ValmisLymfaödeema | Perioperatiiviset/postoperatiiviset komplikaatiot | Vaiheen II Vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Stage IVA Vulvar Cancer AJCC v7 | Vaihe IA Vulvar Cancer AJCC v7 | Vaihe IB Vulvar Cancer AJCC v7 | Vaihe...Yhdysvallat
-
National Cancer Institute (NCI)NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... ja muut yhteistyökumppanitAktiivinen, ei rekrytointiHormonireseptori positiivinen | Vaiheen IA rintasyöpä AJCC v7 | Vaiheen IB rintasyöpä AJCC v7 | Stage IIA Breast Cancer AJCC v6 ja v7 | Vaiheen IIB rintasyöpä AJCC v6 ja v7 | Vaiheen IIIB rintasyöpä AJCC v7 | Rintojen adenokarsinoomaYhdysvallat, Kanada, Australia, Puerto Rico, Uusi Seelanti, Irlanti, Peru, Yhdistynyt kuningaskunta